Volume 53, Issue 6, Pages (June 2008)

Slides:



Advertisements
Similar presentations
Volume 50, Issue 3, Pages (September 2006)
Advertisements

The PSA Era is not Over for Prostate Cancer
Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection 
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis  Maria I. Carlo, Darren R.
Volume 63, Issue 5, Pages (May 2013)
Global Trends in Testicular Cancer Incidence and Mortality
Volume 56, Issue 6, Pages (December 2009)
Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction  Steven A. Kaplan,
A Sealed Laparoscopic Nephroureterectomy: A New Technique
Volume 61, Issue 5, Pages (May 2012)
Volume 50, Issue 5, Pages (November 2006)
Volume 53, Issue 5, Pages (May 2008)
Volume 71, Issue 6, Pages e171-e172 (June 2017)
Let the Games Begin (with EAU Approval)
Volume 73, Issue 5, Pages (May 2018)
Volume 52, Issue 3, Pages (September 2007)
Prostate Cancer Epidemic in Sight?
Volume 45, Issue 4, Pages (April 2004)
Anti–tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: A case report  Philip V. Hassard, Scott W. Binder, Viera.
Volume 57, Issue 5, Pages (May 2010)
Volume 46, Issue 2, Pages (August 2004)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Volume 51, Issue 1, Pages (January 2007)
Volume 52, Issue 3, Pages (September 2007)
Volume 54, Issue 4, Pages (October 2008)
Volume 70, Issue 3, Pages (September 2016)
Volume 51, Issue 2, Pages (February 2007)
Volume 60, Issue 1, Pages (July 2011)
Spread of OnabotulinumtoxinA After Bladder Injection
Volume 72, Issue 3, Pages (September 2017)
Volume 54, Issue 2, Pages (August 2008)
Volume 49, Issue 6, Pages (June 2006)
Prostate Cancer Epidemic in Sight?
James N. Armitage, Stuart O. Irving, Neil A. Burgess  European Urology 
The PSA Era is not Over for Prostate Cancer
Volume 69, Issue 2, Pages (February 2016)
Volume 61, Issue 5, Pages (May 2012)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 66, Issue 2, Pages (August 2014)
Volume 57, Issue 5, Pages (May 2010)
Trends in Hypospadias Surgery: Results of a Worldwide Survey
Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review  Sven van.
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
The Inside-Out Transobturator Male Sling for the Surgical Treatment of Stress Urinary Incontinence After Radical Prostatectomy: Midterm Results of a Single-Center.
Tillmann Loch, Pat Fox Fulgham  European Urology 
Volume 54, Issue 2, Pages (August 2008)
The Economic Costs of Overactive Bladder in Germany
Volume 50, Issue 5, Pages (November 2006)
Volume 55, Issue 6, Pages (June 2009)
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy  Bertrand Tombal, Richard Berges  European Urology.
Volume 52, Issue 6, Pages (December 2007)
Prognostic Impact of Comorbidity in Patients with Bladder Cancer
Volume 53, Issue 6, Pages (June 2008)
Alex Tong Long Lin, An Hang Yang, Kuang-Kuo Chen  European Urology 
European Urology is “Your” Journal
Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg 
Volume 55, Issue 3, Pages (March 2009)
Botulinum Toxin Type A Injections for Treating Neurogenic Detrusor Overactivity Combined With Low-Compliance Bladder in Patients With Spinal Cord Lesions 
Understanding the Role of Botulinum Toxin A in the Treatment of the Overactive Bladder—More than Just Muscle Relaxation  Apostolos Apostolidis, Axel Haferkamp,
Improving Outcomes in Patients With Refractory Idiopathic and Neurogenic Detrusor Overactivity: Management Strategies  David A. Ginsberg, MD, Lynne Kolton.
Improving Flexibility and Quality of Life for Your Patients: A Must?
Profile of Silodosin European Urology Supplements
Economic Burden of Bladder Cancer Across the European Union
Volume 52, Issue 6, Pages (December 2007)
Proposed Mechanism for the Efficacy of Injected Botulinum Toxin in the Treatment of Human Detrusor Overactivity  Apostolos Apostolidis, Prokar Dasgupta,
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Volume 54, Issue 1, Pages (July 2008)
Volume 51, Issue 5, Pages (May 2007)
Presentation transcript:

Volume 53, Issue 6, Pages 1245-1253 (June 2008) Histological Changes in the Urothelium and Suburothelium of Human Overactive Bladder following Intradetrusor Injections of Botulinum Neurotoxin Type A for the Treatment of Neurogenic or Idiopathic Detrusor Overactivity  Apostolos Apostolidis, Thomas S. Jacques, Alex Freeman, Vinay Kalsi, Roshni Popat, Gwendoline Gonzales, Soumendra N. Datta, Shabnam Ghazi-Noori, Sohier Elneil, Prokar Dasgupta, Clare J. Fowler  European Urology  Volume 53, Issue 6, Pages 1245-1253 (June 2008) DOI: 10.1016/j.eururo.2008.02.037 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Percentage of inflammation-positive biopsies before treatment and after one or repeat injections in the whole study population. A trend for increased evidence of inflammatory signs was noted in biopsies taken after the first and repeat injections compared with those obtained before treatment. European Urology 2008 53, 1245-1253DOI: (10.1016/j.eururo.2008.02.037) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 No significant change was seen in degree of inflammation in biopsies taken from the whole study population after the first and repeat injections compared with those obtained before treatment. European Urology 2008 53, 1245-1253DOI: (10.1016/j.eururo.2008.02.037) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 3 Percentage of eosinophil-positive biopsies before treatment and after one or repeat injections in the whole study population. There was increased evidence of eosinophils in biopsies taken after the first and repeat injections compared with those obtained before treatment. European Urology 2008 53, 1245-1253DOI: (10.1016/j.eururo.2008.02.037) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 4 Mean inflammatory score did not change in biopsies obtained after the first injection in either the NDO or IDO subgroup of patients, although a progressive increase was noted in absolute values in the NDO population. European Urology 2008 53, 1245-1253DOI: (10.1016/j.eururo.2008.02.037) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 5 Top panel: representative photographs from (a) NDO specimen and (b) IDO specimen at baseline. No significant difference existed between NDO and IDO bladders in degree of baseline inflammation. Photographs in the bottom panel show the presence of inflammatory findings in NDO specimens after BoNTA treatment. Arrows indicate increased numbers of lymphocytes at 4 wk post-BoNTA (c), and a larger number of lymphocytes forming a well-circumscribed node at 16 wk post-BoNTA (d). Despite the increase in mean values, the inflammatory score remained unchanged compared with baseline. All photos were taken at ×40 magnification. European Urology 2008 53, 1245-1253DOI: (10.1016/j.eururo.2008.02.037) Copyright © 2008 European Association of Urology Terms and Conditions